<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Arq Bras Cardiol</journal-id><journal-id journal-id-type="iso-abbrev">Arq. Bras. Cardiol</journal-id><journal-id journal-id-type="publisher-id">abc</journal-id><journal-title-group><journal-title>Arquivos Brasileiros de Cardiologia</journal-title></journal-title-group><issn pub-type="ppub">0066-782X</issn><issn pub-type="epub">1678-4170</issn><publisher><publisher-name>Sociedade Brasileira de Cardiologia</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26465872</article-id><article-id pub-id-type="pmc">4693664</article-id><article-id pub-id-type="doi">10.5935/abc.20150123</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Renin-Angiotensin System Blockade Associated with Statin Improves
Endothelial Function in Diabetics</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Gismondi</surname><given-names>Ronaldo Altenburg</given-names></name><xref ref-type="aff" rid="aff01"/><xref ref-type="corresp" rid="c01"/></contrib><contrib contrib-type="author"><name><surname>Bedirian</surname><given-names>Ricardo</given-names></name><xref ref-type="aff" rid="aff01"/></contrib><contrib contrib-type="author"><name><surname>Pozzobon</surname><given-names>Cesar Romaro</given-names></name><xref ref-type="aff" rid="aff01"/></contrib><contrib contrib-type="author"><name><surname>Ladeira</surname><given-names>M&#x000e1;rcia Cristina</given-names></name><xref ref-type="aff" rid="aff01"/></contrib><contrib contrib-type="author"><name><surname>Oigman</surname><given-names>Wille</given-names></name><xref ref-type="aff" rid="aff01"/></contrib><contrib contrib-type="author"><name><surname>Neves</surname><given-names>M&#x000e1;rio Fritsch</given-names></name><xref ref-type="aff" rid="aff01"/></contrib><aff id="aff01">Universidade do Estado do Rio de Janeiro, Rio de Janeiro, RJ -
Brazil</aff></contrib-group><author-notes><corresp id="c01"><bold>Mailing Address: Ronaldo Altenburg Gismondi</bold>, Hospital
Universit&#x000e1;rio Ant&#x000f4;nio Pedro, Rua Marqu&#x000ea;s do Paran&#x000e1;, 303 - 7&#x000ba; andar - secretaria de
cl&#x000ed;nica m&#x000e9;dica. Postal Code 24220-300, Niter&#x000f3;i, RJ - Brazil. E-mail:
<email>ronaldo@floralia.com.br</email>,
<email>ronaldogismondi@gmail.com</email></corresp></author-notes><pub-date pub-type="epub-ppub"><month>12</month><year>2015</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><month>12</month><year>2015</year></pub-date><volume>105</volume><issue>6</issue><fpage>597</fpage><lpage>605</lpage><history><date date-type="received"><day>24</day><month>1</month><year>2015</year></date><date date-type="rev-recd"><day>11</day><month>5</month><year>2015</year></date><date date-type="accepted"><day>11</day><month>5</month><year>2015</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution License, which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly
cited.</license-p></license></permissions><abstract><sec><title>Background</title><p>Studies suggest that statins have pleiotropic effects, such as reduction in blood
pressure, and improvement in endothelial function and vascular stiffness.</p></sec><sec><title>Objective</title><p>To analyze if prior statin use influences the effect of
renin-angiotensin-aldosterone system inhibitors on blood pressure, endothelial
function, and vascular stiffness.</p></sec><sec><title>Methods</title><p>Patients with diabetes and hypertension with office systolic blood pressure
&#x02265; 130 mmHg and/or diastolic blood pressure &#x02265; 80 mmHg had their
antihypertensive medications replaced by amlodipine during 6 weeks. They were then
randomized to either benazepril or losartan for 12 additional weeks while
continuing on amlodipine. Blood pressure (assessed with ambulatory blood pressure
monitoring), endothelial function (brachial artery flow-mediated dilation), and
vascular stiffness (pulse wave velocity) were evaluated before and after the
combined treatment. In this study, a post hoc analysis was performed to compare
patients who were or were not on statins (SU and NSU groups, respectively).</p></sec><sec><title>Results</title><p>The SU group presented a greater reduction in the 24-hour systolic blood pressure
(from 134 to 122 mmHg, p = 0.007), and in the brachial artery flow-mediated
dilation (from 6.5 to 10.9%, p = 0.003) when compared with the NSU group (from 137
to 128 mmHg, p = 0.362, and from 7.5 to 8.3%, p = 0.820). There was no
statistically significant difference in pulse wave velocity (SU group: from 9.95
to 9.90 m/s, p = 0.650; NSU group: from 10.65 to 11.05 m/s, p = 0.586).</p></sec><sec><title>Conclusion</title><p>Combined use of statins, amlodipine, and renin-angiotensin-aldosterone system
inhibitors improves the antihypertensive response and endothelial function in
patients with hypertension and diabetes.</p></sec></abstract><kwd-group><kwd>Hypertension</kwd><kwd>Renin-Angiotensin System/drug effects</kwd><kwd>Endothelium/physiopathology</kwd><kwd>Diabetes Mellitus</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Statins are the main LDL-cholesterol lowering drugs. Studies show that these drugs have
pleiotropic effects, such as improvement in endothelial vasodilation response, increase
in nitric oxide bioavailability, and reduction in endothelin levels<sup><xref rid="r01" ref-type="bibr">1</xref>,<xref rid="r02" ref-type="bibr">2</xref></sup>.
These effects are believed to be related to their benefit in populations with high
cardiovascular risk, in which their use is associated with reduced risk of
cardiovascular events<sup><xref rid="r03" ref-type="bibr">3</xref>,<xref rid="r04" ref-type="bibr">4</xref></sup>.</p><p>One of the pleiotropic effects of the statins is the reduction in blood pressure (BP). A
recent meta-analysis that included more than 20 thousand patients showed a reduction of
2.6&#x000a0;mmHg in systolic BP with statins<sup><xref rid="r05" ref-type="bibr">5</xref></sup>.
In addition, this effect was greater in patients undergoing pharmacological treatment
for hypertension, suggesting a potential synergistic mechanism between the
antihypertensive drugs and the statins.</p><p>The aim of this study was to analyze whether the use of statin would influence the
effect of renin-angiotensin-aldosterone system (RAAS) inhibitors on BP, endothelial
function, and vascular stiffness in a population of patients with hypertension and type
2 diabetes mellitus (T2DM).</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Patients Selection</title><p>Patients selected for this project had hypertension and T2DM and were followed up as
outpatients in the internal medicine service at <italic>Universidade do Estado do Rio
de Janeiro (UERJ)</italic>. The inclusion criteria were a previous diagnosis of
hypertension and T2DM, age between 40 and 70 years, and systolic BP&#x000a0;&#x02265;&#x000a0;130 mmHg
and/or diastolic BP&#x000a0;&#x02265;&#x000a0;80 mmHg. The exclusion criteria included resistant
hypertension, insulin use, stages 4 and 5 chronic kidney disease, previous history of
myocardial infarction and/or stroke, stages C and D heart failure, atrial
fibrillation, symptomatic peripheral arterial disease, retinopathy with reduced
visual acuity, nephrotic syndrome, and symptomatic diabetic neuropathy. The study was
approved by the Research Ethics Committee of <italic>Hospital Universit&#x000e1;rio Pedro
Ernesto</italic> (UERJ) under the number 01539612.6.0000.5259. All participants
read and signed a free and informed consent form. The study is registered at
ClinicalTrials.gov under the number NCT01603940.</p></sec><sec><title>Study Design</title><p>The study was an open randomized clinical trial, with two active treatment groups and
without use of placebo. At visit 1, patients underwent a clinical evaluation and had
their antihypertensive medications replaced by amlodipine 5 mg/day. Visit 2 was
conducted 6 weeks later and included clinical and laboratory evaluation, ambulatory
BP monitoring (ABPM), and assessment of endothelial function and vascular stiffness.
During this visit, the patients were randomized to benazepril 10 mg/day or losartan
50 mg/day while continuing on amlodipine. Two reevaluations (visits 3 and 4) were
performed at intervals of 4 weeks for adjustment of BP, which was aimed at values
&#x0003c;&#x000a0;130 x 80 mmHg. The antihypertensive medications in the study could have their
doses doubled (benazepril 20 mg and losartan 100&#x000a0;mg), and the addition of
hydrochlorothiazide 25 mg/day was allowed on visits 3 and 4. The dose of amlodipine
was maintained at 5 mg/day. At the end of 12 weeks of treatment with RAAS inhibitors,
the final visit (visit 5) was conducted, and the assessments performed on visit 2
were repeated. The dose of the T2DM medication was maintained constant. Adherence to
treatment was assessed by a comparison between actual and expected tablet intake. We
evaluated the use of antihypertensive drugs, statins, acetylsalicylic acid, and oral
hypoglycemic agents. Patients were considered as having good adherence when the
actual intake was equal to or greater than 80% of the expected intake.</p></sec><sec><title>Statin Use</title><p>On visit 1, patients were classified as users or non-users of statin (SU and SNU
groups, respectively). Throughout the 18&#x000a0;weeks of the study, the statin was
maintained in those who were already taking it, and was not allowed to be started in
those who were not taking it. The statin used in the study was simvastatin at a dose
of 20 mg/day. All patients in the SU group were taking a statin for more than 12
weeks as prescribed by the physician assistant.</p></sec><sec><title>Conditions to Undergo Complementary Evaluation</title><p>All tests were conducted in the morning after a 12-hour fast. Patients were
instructed to not smoke, consume caffeine, or practice physical activity within 24
hours of the tests. The rooms were air-conditioned and had the temperature set to
around 23 &#x000b1; 2&#x000ba;C and the air relative humidity between 50 and 70%. The patients
were instructed to take the antihypertensive medication 1 to 2 hours prior to the
evaluation.</p></sec><sec><title>Blood Pressure Measurement</title><p>For office BP measurements, the patients sat down and rested for 10 minutes. We used
a semiautomatic, calibrated equipment, model HEM-705CP (Omron Healthcare, Inc., IL,
USA), with the cuff adjusted to the arm circumference. Three measurements were
obtained in each arm, and their respective mean values were calculated. The highest
mean value was used for analysis of the data.</p></sec><sec><title>Ambulatory Blood Pressure Monitoring (ABPM)</title><p>ABPM was assessed with SpaceLabs 90207 (SpaceLabs Inc., WA, USA). The evaluation was
scheduled to start between 8 and 9 a.m. and last for at least 24 hours. The BP was
measured every 20 minutes between 6 a.m. and 11&#x000a0;p.m., and every 30 minutes between 11
p.m. and 6 a.m. The test was considered satisfactory when at least 70% of the
readings were valid, with a minimum of 16 readings during the daytime and 8 readings
during sleep and no more than two hours without measurements. We considered the sleep
time as that reported by the patient in the activities diary. Nocturnal BP reduction
was calculated as [(awake mean BP - sleep mean BP) /awake mean BP] x 100.</p></sec><sec><title>Laboratory Tests</title><p>Venous blood samples were collected after a 12-hour fast for biochemical tests. When
triglyceride levels were &#x0003c; 400 mg/dl, we calculated the LDL-cholesterol fraction
with the Friedewald formula. Glomerular filtration rate (eGFR) was estimated with the
MDRD formula: eGFR&#x000a0;=&#x000a0;186*Creatinine<sup>-1.154*</sup>Age<sup>-0.203</sup>(*0.742 if
female). C-reactive protein was determined by nephelometry (Siemens AG Inc., Munich,
Germany). To measure microalbuminuria, we used the albuminuria/creatinuria ratio
determined in a sample of first-morning urine.</p></sec><sec><title>Vascular Tests</title><sec><title>Brachial Artery Flow-Mediated Dilation (FMD)</title><p>The test was conducted according to the latest guidelines on the method<sup><xref rid="r06" ref-type="bibr">6</xref></sup>. The examiner was blinded to the
patients&#x02019; treatment. We used the ultrasound equipment Vivid 3 (GE Healthcare,
Milwaukee, WI, USA) with a 10 MHz high-resolution linear transducer. The patient
was placed in the supine position, with the right arm abducted. After locating the
brachial artery, the transducer was placed on the anteromedial surface of the
right arm, perpendicular to the axis of the arm, 2 to 5 cm above the antecubital
fossa, on the topography of the brachial artery. The measurements were obtained at
the end of the diastole (R wave on the electrocardiogram). Ischemia was induced by
inflation of the cuff 50 mmHg above the systolic BP during 5 minutes. The largest
diameter of the artery was recorded 30, 60, and 90 seconds after deflation of the
cuff. FMD was calculated as the variation of the largest diameter of the artery in
relation to its baseline measurement.</p></sec><sec><title>Pulse Wave Velocity (PWV)</title><p>Pulse waves were obtained with the equipment Complior SP (Alam Medical, Paris,
France). The transducers were positioned on the right carotid, right radial
(crPWV), and right femoral (cfPWV) arteries<sup><xref rid="r07" ref-type="bibr">7</xref></sup>. The distances between the pulses were obtained directly
with a tape measure. The carotid-femoral distance was multiplied by 0.8, and this
value was used by the equipment for the calculation. Two PWV measurements were
carried out, and when the difference between them was greater than 0.5 m/s, a
third measurement was obtained. The average of these measurements was used for the
analysis.</p></sec><sec><title>Determination of Central Aortic Pressures</title><p>Pulse waves at the right radial artery were obtained with a tonometer (SPC-301 -
Millar Instruments, Texas, USA) calibrated according to the pressure in the
brachial artery. Analysis of this arterial wave by applanation tonometry was
performed to derive central aortic pressures and other hemodynamic parameters
using the system SphygmoCor (Atcor Medical, Sydney, Australia)<sup><xref rid="r08" ref-type="bibr">8</xref></sup>. This software calculated the
central systolic BP, central pulse pressure (PP), augmentation pressure (AP), and
augmentation index (AIx). Two measurements were obtained, and when the difference
between them was greater than 10%, a third measurement was performed. The average
of these measurements was used for the analysis.</p></sec></sec><sec><title>Statistical Analysis</title><p>The data are presented as median (interquartile range) for numeric variables and
distribution of frequencies and proportions for categorical variables. The
Mann-Whitney test and Fisher's exact test were used to compare numerical and
categorical variables, respectively. The Wilcoxon test was used for paired comparison
of variables. Based on a maximum type I error of 0.05 and a standard deviation of
3.5%, a sample size of 14 patients in each group would have 80% power to find a
difference &#x02265;&#x000a0;4% in FMD. The calculation of the sample size used the expected
FMD difference between the benazepril and losartan groups according to the design of
the original study<sup><xref rid="r09" ref-type="bibr">9</xref></sup>. The
statistical analysis was performed using a significance level of 5% and the software
Statistica 12 (Statsoft Inc, Tulsa, OK, USA).</p></sec></sec><sec sec-type="results"><title>Results</title><p>According to the inclusion criteria, 47 patients were selected, and 30 were randomized
to one of the treatment groups (<xref ref-type="fig" rid="f01">Figure 1</xref>). On
visit 1, there were 13 patients in the SU group and 17 patients in the NSU group. All
patients showed good treatment adherence. Baseline demographic, clinical, and laboratory
characteristics of these patients are shown in <xref ref-type="table" rid="t01">Table
1</xref>. After treatment with the angiotensin-converting enzyme inhibitor (ACEI) or
angiotensin receptor blocker (ARB), there was no statistically significant difference in
laboratory parameters between the groups (data not shown).</p><fig id="f01" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Flowchart of the participants throughout the study.</p></caption><graphic xlink:href="abc-105-06-0597-g01"/></fig><table-wrap id="t01" orientation="portrait" position="float"><label>Table 1</label><caption><p>Baseline clinical and laboratory characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">
<bold>Variables</bold>
</th><th align="center" rowspan="1" colspan="1">
<bold>SU (n = 13)</bold>
</th><th align="center" rowspan="1" colspan="1">
<bold>NSU (n = 17)</bold>
</th><th align="center" rowspan="1" colspan="1">
<bold>p value</bold>
</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Age (years)</td><td align="center" rowspan="1" colspan="1">58 (55-60)</td><td align="center" rowspan="1" colspan="1">57 (52-62)</td><td align="center" rowspan="1" colspan="1">0.401</td></tr><tr><td rowspan="1" colspan="1">Male Gender, n (%)</td><td align="center" rowspan="1" colspan="1">7 (53.8)</td><td align="center" rowspan="1" colspan="1">4 (23.5)</td><td align="center" rowspan="1" colspan="1">0.098</td></tr><tr><td rowspan="1" colspan="1">Smoking, n (%)</td><td align="center" rowspan="1" colspan="1">2 (15.3)</td><td align="center" rowspan="1" colspan="1">2 (11.7)</td><td align="center" rowspan="1" colspan="1">0.972</td></tr><tr><td rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">29.4 (26.9-33.3)</td><td align="center" rowspan="1" colspan="1">31.2 (28.1-32.9)</td><td align="center" rowspan="1" colspan="1">0.999</td></tr><tr><td rowspan="1" colspan="1">Glucose (mg/dL)</td><td align="center" rowspan="1" colspan="1">107 (96-119)</td><td align="center" rowspan="1" colspan="1">117 (102-160)</td><td align="center" rowspan="1" colspan="1">0.438</td></tr><tr><td rowspan="1" colspan="1">HbA1c (%)</td><td align="center" rowspan="1" colspan="1">6.25 (5.80-6.70)</td><td align="center" rowspan="1" colspan="1">6.85 (6.30-7.60)</td><td align="center" rowspan="1" colspan="1">0.278</td></tr><tr><td rowspan="1" colspan="1">Creatinine (mg/dL)</td><td align="center" rowspan="1" colspan="1">0.76 (0.60-0.80)</td><td align="center" rowspan="1" colspan="1">0.70 (0.50-0.90)</td><td align="center" rowspan="1" colspan="1">0.899</td></tr><tr><td rowspan="1" colspan="1">eGFR (ml/min)</td><td align="center" rowspan="1" colspan="1">82.8 (77.8-105.7)</td><td align="center" rowspan="1" colspan="1">90.4 (72.6-130.8)</td><td align="center" rowspan="1" colspan="1">0.900</td></tr><tr><td rowspan="1" colspan="1">Potassium (mEq/l)</td><td align="center" rowspan="1" colspan="1">4.5 (4.3-4.7)</td><td align="center" rowspan="1" colspan="1">4.4 (4.0-4.7)</td><td align="center" rowspan="1" colspan="1">0.659</td></tr><tr><td rowspan="1" colspan="1">Uric Acid (mg/dL)</td><td align="center" rowspan="1" colspan="1">6.0 (4.5-6.1)</td><td align="center" rowspan="1" colspan="1">3.6 (3.2-5.1)</td><td align="center" rowspan="1" colspan="1">0.530</td></tr><tr><td rowspan="1" colspan="1">Triglycerides (mg/dL)</td><td align="center" rowspan="1" colspan="1">120 (95-174)</td><td align="center" rowspan="1" colspan="1">132 (102-162)</td><td align="center" rowspan="1" colspan="1">0.964</td></tr><tr><td rowspan="1" colspan="1">Total Cholesterol (mg/dL)</td><td align="center" rowspan="1" colspan="1">186 (167-218)</td><td align="center" rowspan="1" colspan="1">195 (171-217)</td><td align="center" rowspan="1" colspan="1">0.785</td></tr><tr><td rowspan="1" colspan="1">LDL-cholesterol (mg/dL)</td><td align="center" rowspan="1" colspan="1">106 (87-125)</td><td align="center" rowspan="1" colspan="1">117 (103-131)</td><td align="center" rowspan="1" colspan="1">0.645</td></tr><tr><td rowspan="1" colspan="1">HDL-cholesterol (mg/dL)</td><td align="center" rowspan="1" colspan="1">53 (49-56)</td><td align="center" rowspan="1" colspan="1">49 (44-59)</td><td align="center" rowspan="1" colspan="1">0.524</td></tr><tr><td rowspan="1" colspan="1">C-Reactive Protein (mg/dL)</td><td align="center" rowspan="1" colspan="1">0.18 (0.07-0.50)</td><td align="center" rowspan="1" colspan="1">0.48 (0.18-0.63)</td><td align="center" rowspan="1" colspan="1">0.089</td></tr><tr><td rowspan="1" colspan="1">ACR (mg/g)</td><td align="center" rowspan="1" colspan="1">16 (10-24)</td><td align="center" rowspan="1" colspan="1">14 (9-24)</td><td align="center" rowspan="1" colspan="1">0.747</td></tr><tr><td rowspan="1" colspan="1">Benazepril, n(%)</td><td align="center" rowspan="1" colspan="1">7 (53.8)</td><td align="center" rowspan="1" colspan="1">7 (41.1)</td><td align="center" rowspan="1" colspan="1">0.513</td></tr><tr><td rowspan="1" colspan="1">Metformin, n(%)</td><td align="center" rowspan="1" colspan="1">12 (92.3)</td><td align="center" rowspan="1" colspan="1">15 (88.2)</td><td align="center" rowspan="1" colspan="1">0.747</td></tr><tr><td rowspan="1" colspan="1">Sulphonylurea, n(%)</td><td align="center" rowspan="1" colspan="1">4 (30.7)</td><td align="center" rowspan="1" colspan="1">6 (35.3)</td><td align="center" rowspan="1" colspan="1">0.817</td></tr></tbody></table><table-wrap-foot><fn id="TFN01"><p>Values are expressed as median (interquartile range), except where specified
otherwise; SU: Statin users group; NSU: Non-statin users group; BMI: Body mass
index; HbA1c: Glycated hemoglobin; eGFR: Estimated glomerular filtration rate;
LDL: Low-density lipoprotein; HDL: High-density lipoprotein; ACR:
Albumin-creatinine ratio.</p></fn></table-wrap-foot></table-wrap><sec><title>Blood Pressure</title><p>In the analysis of the office BP in the SU group, there was a non-significant
decrease in diastolic (8.0 mmHg or 9% reduction) and systolic BP (11.6 mmHg or 8%
reduction), although no statistical significance was observed (<xref ref-type="fig" rid="f02">Figure&#x000a0;2</xref>). In the ABPM analysis, the SU group exhibited a greater
reduction in mean 24-hour systolic BP (11.5 mmHg or 9% reduction) (<xref ref-type="fig" rid="f03">Figure&#x000a0;3</xref> and <xref ref-type="table" rid="t02">Table 2</xref>). A similar effect was observed in the mean 24-hour diastolic BP
(4.0 mmHg or 5% reduction) and PP (7.0 mmHg or 13% reduction) (<xref ref-type="table" rid="t02">Table 2</xref>).</p><fig id="f02" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Comparison of office systolic and diastolic blood pressure values between the
SU and NSU groups before and after association of antihypertensive treatment;
SU: Statin users group; NSU: Non-statin users group; *p = 0.100, patients in
the SU group before and after treatment; &#x02020;p = 0.016, patients in the SU
group before and after treatment.</p></caption><graphic xlink:href="abc-105-06-0597-g02"/></fig><fig id="f03" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Comparison of mean 24-hour systolic and diastolic blood pressures in the SU and
NSU groups before and after association of antihypertensive treatment; SU:
Statin users group; NSU: Non-statin users group; *p = 0.007, patients in the SU
group before and after treatment.</p></caption><graphic xlink:href="abc-105-06-0597-g03"/></fig><table-wrap id="t02" orientation="portrait" position="float"><label>Table 2</label><caption><p>Effect of statin use on ABPM.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="left" colspan="1">
<bold>Variables</bold>
</th><th colspan="2" align="center" style="border-bottom-style:solid; border-bottom-width:thin" rowspan="1">
<bold>SU</bold>
</th><th colspan="2" align="center" style="border-bottom-style:solid; border-bottom-width:thin" rowspan="1">
<bold>NSU</bold>
</th><th colspan="3" align="center" style="border-bottom-style:solid; border-bottom-width:thin" rowspan="1">
<bold>p value</bold>
</th></tr><tr><th align="center" rowspan="1" colspan="1">
<bold>Before</bold>
</th><th align="center" rowspan="1" colspan="1">
<bold>After</bold>
</th><th align="center" rowspan="1" colspan="1">
<bold>Before</bold>
</th><th align="center" rowspan="1" colspan="1">
<bold>After</bold>
</th><th align="center" rowspan="1" colspan="1">
<bold>p1</bold>
</th><th align="center" rowspan="1" colspan="1">
<bold>p2</bold>
</th><th align="center" rowspan="1" colspan="1">
<bold>p3</bold>
</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">SBP 24-h ABPM</td><td align="center" rowspan="1" colspan="1">134 (120-146)</td><td align="center" rowspan="1" colspan="1">122 (114-135)</td><td align="center" rowspan="1" colspan="1">137 (122-149)</td><td align="center" rowspan="1" colspan="1">128 (122-140)</td><td align="center" rowspan="1" colspan="1">0.007</td><td align="center" rowspan="1" colspan="1">0.362</td><td align="center" rowspan="1" colspan="1">0.333</td></tr><tr><td rowspan="1" colspan="1">DBP 24-h ABPM</td><td align="center" rowspan="1" colspan="1">79 (73-86)</td><td align="center" rowspan="1" colspan="1">75 (67-84)</td><td align="center" rowspan="1" colspan="1">78 (76-89)</td><td align="center" rowspan="1" colspan="1">78 (63-90)</td><td align="center" rowspan="1" colspan="1">0.007</td><td align="center" rowspan="1" colspan="1">0.209</td><td align="center" rowspan="1" colspan="1">0.976</td></tr><tr><td rowspan="1" colspan="1">PP 24-h ABPM</td><td align="center" rowspan="1" colspan="1">56 (49-61)</td><td align="center" rowspan="1" colspan="1">49 (41-55)</td><td align="center" rowspan="1" colspan="1">51 (45-62)</td><td align="center" rowspan="1" colspan="1">56 (44-61)</td><td align="center" rowspan="1" colspan="1">0.032</td><td align="center" rowspan="1" colspan="1">0.813</td><td align="center" rowspan="1" colspan="1">0.177</td></tr><tr><td rowspan="1" colspan="1">Awake SBP</td><td align="center" rowspan="1" colspan="1">139 (121-149)</td><td align="center" rowspan="1" colspan="1">125 (115-136)</td><td align="center" rowspan="1" colspan="1">139 (125-156)</td><td align="center" rowspan="1" colspan="1">130 (123-147)</td><td align="center" rowspan="1" colspan="1">0.015</td><td align="center" rowspan="1" colspan="1">0.167</td><td align="center" rowspan="1" colspan="1">0.333</td></tr><tr><td rowspan="1" colspan="1">Awake DBP</td><td align="center" rowspan="1" colspan="1">81 (74-89)</td><td align="center" rowspan="1" colspan="1">77 (72-83)</td><td align="center" rowspan="1" colspan="1">81 (78-92)</td><td align="center" rowspan="1" colspan="1">80 (66-90)</td><td align="center" rowspan="1" colspan="1">0.058</td><td align="center" rowspan="1" colspan="1">0.099</td><td align="center" rowspan="1" colspan="1">0.930</td></tr><tr><td rowspan="1" colspan="1">Nocturnal SBP</td><td align="center" rowspan="1" colspan="1">125 (112-139)</td><td align="center" rowspan="1" colspan="1">113 (109-119)</td><td align="center" rowspan="1" colspan="1">134 (116-137)</td><td align="center" rowspan="1" colspan="1">121 (109-132)</td><td align="center" rowspan="1" colspan="1">0.035</td><td align="center" rowspan="1" colspan="1">0.396</td><td align="center" rowspan="1" colspan="1">0.278</td></tr><tr><td rowspan="1" colspan="1">Nocturnal DBP</td><td align="center" rowspan="1" colspan="1">72 (67-76)</td><td align="center" rowspan="1" colspan="1">67 (58-73)</td><td align="center" rowspan="1" colspan="1">73 (66-83)</td><td align="center" rowspan="1" colspan="1">67 (62-80)</td><td align="center" rowspan="1" colspan="1">0.035</td><td align="center" rowspan="1" colspan="1">0.615</td><td align="center" rowspan="1" colspan="1">0.769</td></tr><tr><td rowspan="1" colspan="1">Nocturnal Descent (%)</td><td align="center" rowspan="1" colspan="1">5.0 (2.2-11.7)</td><td align="center" rowspan="1" colspan="1">7.4 (2.9-11.5)</td><td align="center" rowspan="1" colspan="1">10.2 (4.3-13.3)</td><td align="center" rowspan="1" colspan="1">6.4 (4.6-8.2)</td><td align="center" rowspan="1" colspan="1">0.374</td><td align="center" rowspan="1" colspan="1">0.432</td><td align="center" rowspan="1" colspan="1">0.578</td></tr></tbody></table><table-wrap-foot><fn id="TFN02"><p>Values are expressed as median (interquartile range), except where specified
otherwise; unit: mmHg; p1: Patients in the SU group before and after
treatment; p2: Patients in the NSU group before and after treatment; p3:
Comparison between the SU and NSU groups at the end of the treatment; SU:
Statin users group; NSU: Non-statin users group; SBP: Systolic blood
pressure; DBP: Diastolic blood pressure; PP: Pulse pressure; ABPM:
Ambulatory blood pressure monitoring.</p></fn></table-wrap-foot></table-wrap><p>There was a similar percentage of patients using ACEI (54 vs 41%) and ARB (46 vs 59%)
in the SU and SNU groups, and a similar proportion of patients who required dosage
adjustment of these medications (61% vs 47%, p&#x000a0;=&#x000a0;0.430) and/or association of
hydrochlorothiazide for BP control (15% vs 17%, p = 0.865).</p></sec><sec><title>Endothelial Function and Vascular Stiffness</title><p>The SU group presented a greater FMD response and a higher reduction in systolic
aortic BP when compared with the NSU group (<xref ref-type="fig" rid="f04">Figure
4</xref>). There was no statistically significant difference in AIx, cfPWV, and
crPWV responses (<xref ref-type="table" rid="t03">Table 3</xref>).</p><fig id="f04" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Comparison of the values of brachial artery flow-mediated dilation between the
SU and NSU groups before and after association of antihypertensive treatment;
SU: Statin users group; FMD: Brachial artery flow-mediated dilation; NSU:
Non-statin users group; *p = 0.003, patients in the SU group before and after
treatment.</p></caption><graphic xlink:href="abc-105-06-0597-g04"/></fig><table-wrap id="t03" orientation="portrait" position="float"><label>Table 3</label><caption><p>Effect of statin use vascular tests</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="left" colspan="1">
<bold>Variables</bold>
</th><th colspan="2" align="center" style="border-bottom-style:solid; border-bottom-width:thin" rowspan="1">
<bold>SU</bold>
</th><th colspan="2" align="center" style="border-bottom-style:solid; border-bottom-width:thin" rowspan="1">
<bold>NSU</bold>
</th><th colspan="3" align="center" style="border-bottom-style:solid; border-bottom-width:thin" rowspan="1">
<bold>p value</bold>
</th></tr><tr><th align="center" rowspan="1" colspan="1">
<bold>Before</bold>
</th><th align="center" rowspan="1" colspan="1">
<bold>After</bold>
</th><th align="center" rowspan="1" colspan="1">
<bold>Before</bold>
</th><th align="center" rowspan="1" colspan="1">
<bold>After</bold>
</th><th align="center" rowspan="1" colspan="1">
<bold>p 1</bold>
</th><th align="center" rowspan="1" colspan="1">
<bold>p 2</bold>
</th><th align="center" rowspan="1" colspan="1">
<bold>p 3</bold>
</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Brachial FMD (%)</td><td align="center" rowspan="1" colspan="1">6.50 (5.10-7.10)</td><td align="center" rowspan="1" colspan="1">10.90 (7.30-12.20)</td><td align="center" rowspan="1" colspan="1">7.50 (6.00-10.20)</td><td align="center" rowspan="1" colspan="1">8.30 (7.50-9.95)</td><td align="center" rowspan="1" colspan="1">0.003</td><td align="center" rowspan="1" colspan="1">0.820</td><td align="center" rowspan="1" colspan="1">0.211</td></tr><tr><td rowspan="1" colspan="1">cfPWV (m/s)</td><td align="center" rowspan="1" colspan="1">9.95 (9.35-10.55)</td><td align="center" rowspan="1" colspan="1">9.90 (8.50-11.05)</td><td align="center" rowspan="1" colspan="1">10.65 (9.60-12.35)</td><td align="center" rowspan="1" colspan="1">11.05 (10.20-11.70)</td><td align="center" rowspan="1" colspan="1">0.650</td><td align="center" rowspan="1" colspan="1">0.586</td><td align="center" rowspan="1" colspan="1">0.111</td></tr><tr><td rowspan="1" colspan="1">crPWV (m/s)</td><td align="center" rowspan="1" colspan="1">9.85 (9.05-10.40)</td><td align="center" rowspan="1" colspan="1">10.00 (9.05-10.55)</td><td align="center" rowspan="1" colspan="1">9.70 (9.35-10.90)</td><td align="center" rowspan="1" colspan="1">9.65 (9.35-10.20)</td><td align="center" rowspan="1" colspan="1">0.972</td><td align="center" rowspan="1" colspan="1">0.570</td><td align="center" rowspan="1" colspan="1">0.490</td></tr><tr><td rowspan="1" colspan="1">Aortic systolic BP (mmHg)</td><td align="center" rowspan="1" colspan="1">139 (128-143)</td><td align="center" rowspan="1" colspan="1">125 (117-128)</td><td align="center" rowspan="1" colspan="1">127 (121-140)</td><td align="center" rowspan="1" colspan="1">126 (119-139)</td><td align="center" rowspan="1" colspan="1">0.046</td><td align="center" rowspan="1" colspan="1">0.623</td><td align="center" rowspan="1" colspan="1">0.477</td></tr><tr><td rowspan="1" colspan="1">Aortic PP (mmHg)</td><td align="center" rowspan="1" colspan="1">86 (84-92)</td><td align="center" rowspan="1" colspan="1">82 (68-84)</td><td align="center" rowspan="1" colspan="1">82 (79-87)</td><td align="center" rowspan="1" colspan="1">79 (74-88)</td><td align="center" rowspan="1" colspan="1">0.018</td><td align="center" rowspan="1" colspan="1">0.508</td><td align="center" rowspan="1" colspan="1">0.706</td></tr><tr><td rowspan="1" colspan="1">AIx (%)</td><td align="center" rowspan="1" colspan="1">30 (28-43)</td><td align="center" rowspan="1" colspan="1">33 (25-40)</td><td align="center" rowspan="1" colspan="1">31 (23-33)</td><td align="center" rowspan="1" colspan="1">33 (27-37)</td><td align="center" rowspan="1" colspan="1">0.263</td><td align="center" rowspan="1" colspan="1">0.308</td><td align="center" rowspan="1" colspan="1">0.916</td></tr><tr><td rowspan="1" colspan="1">AP (mmHg)</td><td align="center" rowspan="1" colspan="1">15 (13-24)</td><td align="center" rowspan="1" colspan="1">17 (10-21)</td><td align="center" rowspan="1" colspan="1">13 (9-18)</td><td align="center" rowspan="1" colspan="1">16 (10-20)</td><td align="center" rowspan="1" colspan="1">0.278</td><td align="center" rowspan="1" colspan="1">0.320</td><td align="center" rowspan="1" colspan="1">0.966</td></tr></tbody></table><table-wrap-foot><fn id="TFN03"><p>Values are expressed as median (interquartile range), except where specified
otherwise; p1: Patients in the SU group before and after treatment; p2:
Patients in the NSU group before and after treatment; p3: Comparison between
the SU and NSU groups at the end of the treatment; SU: Statin users group;
NSU: Non-statin users group; Brachial FMD: Brachial artery flow-mediated
dilation; cfPWV: Carotid-femoral pulse wave velocity; crPWV: Carotid-radial
pulse wave velocity; BP: Blood pressure; PP: Pulse pressure; AIx:
Augmentation index; AP: Augmentation pressure.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>The most recent guidelines recommend that patients with T2DM should use RAAS inhibitors
(ACEI or ARB) and statins<sup><xref rid="r10" ref-type="bibr">10</xref>-<xref rid="r13" ref-type="bibr">13</xref></sup>. The present study showed that
simvastatin improves endothelial function and increases the antihypertensive effect of
ACEI or ARB in association with amlodipine in patients with hypertension and
diabetes.</p><p>The antihypertensive mechanisms of the statins are probably due to an increase in nitric
oxide bioavailability with an increase in endothelium-dependent vasodilation response,
and a reduction in endothelin-1 concentration and free radicals formation<sup><xref rid="r01" ref-type="bibr">1</xref>,<xref rid="r02" ref-type="bibr">2</xref>,<xref rid="r14" ref-type="bibr">14</xref></sup>. In addition, a synergism is also
speculated between statins and RAAS inhibitors through reduced expression of type 1
angiotensin receptors and blockade of intracellular pathways associated with angiotensin
II action, both caused by statins<sup><xref rid="r15" ref-type="bibr">15</xref></sup>.
Many of these benefiting mechanisms of the statins are independent of the reduction in
LDL-cholesterol. In the present study, the reduction in BP and improvement in
endothelial function occurred despite statistically similar LDL-cholesterol values in
the SU and NSU groups.</p><p>In a recent meta-analysis, Briasoulis et al.<sup><xref rid="r05" ref-type="bibr">5</xref></sup> observed a mean systolic BP reduction of 2.6 mmHg in patients on
statins, even in those without a diagnosis of hypertension<sup><xref rid="r05" ref-type="bibr">5</xref></sup>. In hypertensive patients, the systolic BP may reduce up
to 5.8 mmHg<sup><xref rid="r05" ref-type="bibr">5</xref></sup>. In diabetics, the study
estimated a reduction of 6.5 mmHg in the systolic BP and 4.0 mmHg in the diastolic
BP<sup><xref rid="r05" ref-type="bibr">5</xref></sup>. Another meta-analysis by
Strazzullo et al. also examined the antihypertensive effect of statins and observed an
average reduction of 4.0 mmHg in the systolic and 1.2 mmHg in the diastolic BP<sup><xref rid="r16" ref-type="bibr">16</xref></sup>. Strazzullo et al<sup><xref rid="r16" ref-type="bibr">16</xref></sup> observed in a subgroup of diabetic
patients a reduction of 3.7 mmHg in the systolic and 0.8 mmHg in the diastolic
BP<sup><xref rid="r16" ref-type="bibr">16</xref></sup>. None of these studies
investigated the association of statins with ACEI or ARB.</p><p>Sp&#x000f3;sito et al<sup><xref rid="r17" ref-type="bibr">17</xref></sup> studied the
interaction between ACEI and statins and observed that the group receiving a combination
of both showed greater BP reduction when compared with the group receiving ACEI alone
(21 vs. 14 mmHg, p&#x000a0;&#x0003c;&#x000a0;0.05)<sup><xref rid="r17" ref-type="bibr">17</xref></sup>.
However, Mancia et al<sup><xref rid="r18" ref-type="bibr">18</xref></sup> observed no
reduction in BP with the association of pravastatin and fosinopril. Koh et al<sup><xref rid="r19" ref-type="bibr">19</xref></sup> evaluated the combination of losartan
and ramipril with simvastatin and did not observe greater BP reduction with this
association<sup><xref rid="r19" ref-type="bibr">19</xref>,<xref rid="r20" ref-type="bibr">20</xref></sup>. In the present study, the association of benazepril or
losartan in patients already receiving simvastatin and amlodipine promoted greater
reduction in systolic and diastolic BP, both in casual measurements in the office and in
24-hour measurements.</p><p>Zhang et al<sup><xref rid="r21" ref-type="bibr">21</xref></sup> recently published a
meta-analysis on the effects of statins in brachial artery FMD in patients with T2DM.
The final result showed an improvement of 0.94% (95%&#x000a0;CI&#x000a0;0.38-1.50%, p &#x0003c; 0.001) in
absolute FMD values. Koh et al<sup><xref rid="r19" ref-type="bibr">19</xref></sup>
conducted a study in which patients were randomized to three groups: ramipril,
simvastatin, or a combination of both. Their cohort, comprised of 76% of hypertensive
patients, included individuals with a mean age of 60 years, T2DM, and LDL-cholesterol
&#x0003e; 100 mg/dL. The authors observed that the combined use of statins and ACEI promoted
a greater increase in FMD than each medication alone. In contrast, no improvement in FMD
was observed by Van Venrooij et al<sup><xref rid="r22" ref-type="bibr">22</xref></sup>
with atorvastatin, and Beishizen et al. with cerivastatin and simvastatin<sup><xref rid="r22" ref-type="bibr">22</xref>,<xref rid="r23" ref-type="bibr">23</xref></sup>. Tan et al<sup><xref rid="r24" ref-type="bibr">24</xref></sup>, in a
population with T2DM and dyslipidemia, observed an improvement in FMD with atorvastatin
when compared with placebo. In the present study, which assessed a population of
diabetic patients with hypertension, only those already using simvastatin had a
statistically significant improvement in brachial artery FMD when benazepril or losartan
were associated.</p><p>Kanaki et al<sup><xref rid="r25" ref-type="bibr">25</xref></sup> evaluated the use of
simvastatin in patients with hypertension and dyslipidemia and observed improvements in
PWV, aortic BP, and AIx. However, no improvement in aortic pressure was observed with
atorvastatin by William et al<sup><xref rid="r26" ref-type="bibr">26</xref></sup> in
hypertensive patients and Fasset et al<sup><xref rid="r27" ref-type="bibr">27</xref></sup> in patients with chronic renal failure<sup><xref rid="r26" ref-type="bibr">26</xref>,<xref rid="r27" ref-type="bibr">27</xref></sup>. Raisone et
al<sup><xref rid="r28" ref-type="bibr">28</xref></sup> were one of the few to
observe worsening in PWV with atorvastatin. In contrast, Pirro et al<sup><xref rid="r29" ref-type="bibr">29</xref></sup> and Maki-Petaja et al<sup><xref rid="r30" ref-type="bibr">30</xref></sup> observed improvement in PWV with
statins. So far, there are no studies on the effects of statins on aortic pressure and
PWV in diabetic patients with hypertension. The present study showed a reduction in
central aortic pressure, in parallel with reductions in office BP and ABPM in
simvastatin users, although no statistically significant changes were observed in AIx
and PWV.</p><p>The study has some limitations. Since this is a <italic>post hoc</italic> analysis, the
groups were not randomized according to statin use. In addition, approximately half of
the study sample had no prior use of statin. Although it was not possible to evaluate
the reasons, the group without prior use of simvastatin could have pre-selected patients
with poor adherence to antihypertensive drugs before recruitment for the study. These
patients could have BP levels above the recommended target, higher prevalence of
vascular lesions, and as a result, inadequate response to antihypertensive drugs or
lower improvement in endothelial function with the treatment when compared with the
group of statin users. There was also a trend towards more male patients in the group of
simvastatin users. We believe that this fact had little relevance, because despite
having a higher cardiovascular risk, this group had the greatest benefit in BP
reduction. The open use of the medication is also a limiting factor. However, the
results were reinforced by the BP reduction in the ABPM and in central aortic
measurements, since these methods are known to be minimally influenced by the placebo
effect.</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>Prior use of statin increases the antihypertensive effect and improves the endothelial
function in hypertensive patients with T2DM treated with amlodipine associated with an
RAAS inhibitor. Randomized studies with larger samples and 2x2 design are needed to
evaluate the interaction between statins and RAAS inhibitors.</p></sec></body><back><fn-group><fn fn-type="con"><p>
<bold>Author contributions</bold>
</p><p>Conception and design of the research and Analysis and interpretation of the data:
Gismondi RA, Bedirian R, Pozzobon CR, Ladeira MC, Oigman W, Neves MF; Acquisition of
data: Gismondi RA, Bedirian R, Pozzobon CR, Ladeira MC; Statistical analysis and
Critical revision of the manuscript for intellectual content: Gismondi RA, Oigman W,
Neves MF; Obtaining financing: Oigman W, Neves MF; Writing of the manuscript:
Gismondi RA, Bedirian R, Oigman W, Neves MF.</p></fn><fn fn-type="conflict"><p>
<bold>Potential Conflict of Interest</bold>
</p><p>No potential conflict of interest relevant to this article was reported.</p></fn><fn fn-type="supported-by"><p>
<bold>Sources of Funding</bold>
</p><p>This study was funded by Faperj and CNPq.</p></fn><fn fn-type="other"><p>
<bold>Study Association</bold>
</p><p>This article is part of the thesis of Doctoral submitted by Ronaldo Altenburg
Gismondi, from Universidade do Estado do Rio de Janeiro.</p></fn></fn-group><ref-list><title>References</title><ref id="r01"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarkar</surname><given-names>K</given-names></name><name><surname>Sinha</surname><given-names>AK</given-names></name><name><surname>Mehta</surname><given-names>JL</given-names></name></person-group><article-title>The role of statins in endothelial dysfunction in
hypertension</article-title><source>Curr Opin Cardiol</source><year>2006</year><volume>21</volume><issue>4</issue><fpage>316</fpage><lpage>321</lpage><pub-id pub-id-type="pmid">16755200</pub-id></element-citation></ref><ref id="r02"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Sotomayor</surname><given-names>MA</given-names></name><name><surname>P&#x000e9;rez-Guerrero</surname><given-names>C</given-names></name><name><surname>Herrrera</surname><given-names>MD</given-names></name><name><surname>Jimenez</surname><given-names>L</given-names></name><name><surname>Mar&#x000ed;n</surname><given-names>R</given-names></name><name><surname>Marhuenda</surname><given-names>E</given-names></name><etal/></person-group><article-title>Improvement of age-related endothelial dysfunction by simvastatin:
effect on NO and COX pathways</article-title><source>Br J Pharmacol</source><year>2005</year><volume>146</volume><issue>8</issue><fpage>1130</fpage><lpage>1138</lpage><pub-id pub-id-type="pmid">16231003</pub-id></element-citation></ref><ref id="r03"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ribeiro</surname><given-names>RA</given-names></name><name><surname>Duncan</surname><given-names>BB</given-names></name><name><surname>Ziegelmann</surname><given-names>PK</given-names></name><name><surname>Stella</surname><given-names>SF</given-names></name><name><surname>Vieira JL da</surname><given-names>C</given-names></name><name><surname>Restelatto</surname><given-names>LMF</given-names></name><etal/></person-group><article-title>Cost-effectiveness of high, moderate and low-dose statins in the
prevention of vascular events in the Brazilian public health
system</article-title><source>Arq Bras Cardiol</source><year>2014</year><volume>104</volume><issue>1</issue><fpage>32</fpage><lpage>44</lpage><pub-id pub-id-type="pmid">25409878</pub-id></element-citation></ref><ref id="r04"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Vera</surname><given-names>MA</given-names></name><name><surname>Bhole</surname><given-names>V</given-names></name><name><surname>Burns</surname><given-names>LC</given-names></name><name><surname>Lacaille</surname><given-names>D</given-names></name></person-group><article-title>Impact of statin adherence on cardiovascular disease and mortality
outcomes: a systematic review</article-title><source>Br J Clin Pharmacol</source><year>2014</year><volume>78</volume><issue>4</issue><fpage>684</fpage><lpage>698</lpage><pub-id pub-id-type="pmid">25364801</pub-id></element-citation></ref><ref id="r05"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Briasoulis</surname><given-names>A</given-names></name><name><surname>Agarwal</surname><given-names>V</given-names></name><name><surname>Valachis</surname><given-names>A</given-names></name><name><surname>Messerli</surname><given-names>FH</given-names></name></person-group><article-title>Antihypertensive effects of statins: a meta-analysis of prospective
controlled studies</article-title><source>J Clin Hypertens (Greenwich)</source><year>2013</year><volume>15</volume><issue>5</issue><fpage>310</fpage><lpage>320</lpage><pub-id pub-id-type="pmid">23614844</pub-id></element-citation></ref><ref id="r06"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corretti</surname><given-names>MC</given-names></name><name><surname>Anderson</surname><given-names>TJ</given-names></name><name><surname>Benjamin</surname><given-names>EJ</given-names></name><name><surname>Celermajer</surname><given-names>D</given-names></name><name><surname>Charbonneau</surname><given-names>F</given-names></name><name><surname>Creager</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Guidelines for the ultrasound assessment of endothelial-dependent
flow-mediated vasodilation of the brachial artery: a report of the International
Brachial Artery Reactivity Task Force</article-title><source>J Am Coll Cardiol</source><year>2002</year><volume>39</volume><issue>2</issue><fpage>257</fpage><lpage>265</lpage><pub-id pub-id-type="pmid">11788217</pub-id></element-citation></ref><ref id="r07"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laurent</surname><given-names>S</given-names></name><name><surname>Cockcroft</surname><given-names>J</given-names></name><name><surname>Van Bortel</surname><given-names>L</given-names></name><name><surname>Boutouyrie</surname><given-names>P</given-names></name><name><surname>Giannattasio</surname><given-names>C</given-names></name><name><surname>Hayoz</surname><given-names>D</given-names></name><etal/></person-group><article-title>Expert consensus document on arterial stiffness: methodological issues
and clinical applications</article-title><source>Eur Heart J</source><year>2006</year><volume>27</volume><issue>21</issue><fpage>2588</fpage><lpage>2605</lpage><pub-id pub-id-type="pmid">17000623</pub-id></element-citation></ref><ref id="r08"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pauca</surname><given-names>AL</given-names></name><name><surname>O'Rourke</surname><given-names>MF</given-names></name><name><surname>Kon</surname><given-names>ND</given-names></name></person-group><article-title>Prospective evaluation of a method for estimating ascending aortic
pressure from the radial artery pressure waveform</article-title><source>Hypertension</source><year>2001</year><volume>38</volume><issue>4</issue><fpage>932</fpage><lpage>937</lpage><pub-id pub-id-type="pmid">11641312</pub-id></element-citation></ref><ref id="r09"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gismondi</surname><given-names>RA</given-names></name><name><surname>Oigman</surname><given-names>W</given-names></name><name><surname>Bedirian</surname><given-names>R</given-names></name><name><surname>Pozzobon</surname><given-names>CR</given-names></name><name><surname>Ladeira</surname><given-names>MB</given-names></name><name><surname>Neves</surname><given-names>MF</given-names></name></person-group><article-title>Comparison of benazepril and losartan on endothelial function and
vascular stiffness in patients with Type 2 diabetes mellitus and hypertension: A
randomized controlled trial</article-title><source>J Renin Angiotensin Aldosterone Syst</source><day>17</day><month>3</month><year>2015</year><comment>epub ahead of print</comment></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xavier</surname><given-names>HT</given-names></name><name><surname>Izar</surname><given-names>MC</given-names></name><name><surname>Faria</surname><given-names>JR</given-names><suffix>Neto</suffix></name><name><surname>Assad</surname><given-names>MH</given-names></name><name><surname>Rocha</surname><given-names>VZ</given-names></name><name><surname>Sposito</surname><given-names>AC</given-names></name><etal/></person-group><article-title>V Brazilian Guidelines on Dyslipidemias and Prevention of
Atherosclerosis</article-title><source>Arq Bras Cardiol</source><year>2013</year><volume>101</volume><issue>4</issue><supplement> 1</supplement><fpage>1</fpage><lpage>20</lpage></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mancia</surname><given-names>G</given-names></name><name><surname>Fagard</surname><given-names>R</given-names></name><name><surname>Narkiewicz</surname><given-names>K</given-names></name><name><surname>Redon</surname><given-names>J</given-names></name><name><surname>Zanchetti</surname><given-names>A</given-names></name><name><surname>B&#x000f6;hm</surname><given-names>M</given-names></name><etal/></person-group><article-title>2013 ESH/ESC guidelines for the management of arterial hypertension:
the Task Force for the Management of Arterial Hypertension of the European Society
of Hypertension (ESH) and of the European Society of Cardiology
(ESC)</article-title><source>Eur Heart J</source><year>2013</year><volume>34</volume><issue>28</issue><fpage>2159</fpage><lpage>2219</lpage><pub-id pub-id-type="pmid">23771844</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drapala</surname><given-names>A</given-names></name><name><surname>Sikora</surname><given-names>M</given-names></name><name><surname>Ufnal</surname><given-names>M</given-names></name></person-group><article-title>Statins, the renin-angiotensin-aldosterone system and hypertension - a
tale of another beneficial effect of statins</article-title><source>J Renin Angiotensin Aldosterone Syst</source><year>2014</year><volume>15</volume><issue>3</issue><fpage>250</fpage><lpage>258</lpage><pub-id pub-id-type="pmid">25037529</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lafeber</surname><given-names>M</given-names></name><name><surname>Grobbee</surname><given-names>DE</given-names></name><name><surname>Spiering</surname><given-names>W</given-names></name><name><surname>van der Graaf</surname><given-names>Y</given-names></name><name><surname>Bots</surname><given-names>ML</given-names></name><name><surname>Visseren</surname><given-names>FLJ</given-names></name></person-group><article-title>The combined use of aspirin, a statin, and blood pressure-lowering
agents (polypill components) in clinical practice in patients with vascular
diseases or type 2 diabetes mellitus</article-title><source>Eur J Prev Cardiol</source><year>2013</year><volume>20</volume><issue>5</issue><fpage>771</fpage><lpage>778</lpage><pub-id pub-id-type="pmid">22649123</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wassmann</surname><given-names>S</given-names></name><name><surname>Laufs</surname><given-names>U</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>K</given-names></name><name><surname>Konkol</surname><given-names>C</given-names></name><name><surname>Ahlbory</surname><given-names>K</given-names></name><name><surname>B&#x000e4;umer</surname><given-names>AT</given-names></name><etal/></person-group><article-title>Cellular antioxidant effects of atorvastatin in vitro and in
vivo</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2002</year><volume>22</volume><issue>2</issue><fpage>300</fpage><lpage>305</lpage><pub-id pub-id-type="pmid">11834532</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delbosc</surname><given-names>S</given-names></name><name><surname>Cristol</surname><given-names>J-P</given-names></name><name><surname>Descomps</surname><given-names>B</given-names></name><name><surname>Mimran</surname><given-names>A</given-names></name><name><surname>Jover</surname><given-names>B</given-names></name></person-group><article-title>Simvastatin prevents angiotensin II-induced cardiac alteration and
oxidative stress</article-title><source>Hypertension</source><year>2002</year><volume>40</volume><issue>2</issue><fpage>142</fpage><lpage>147</lpage><pub-id pub-id-type="pmid">12154104</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strazzullo</surname><given-names>P</given-names></name><name><surname>Kerry</surname><given-names>SM</given-names></name><name><surname>Barbato</surname><given-names>A</given-names></name><name><surname>Versiero</surname><given-names>M</given-names></name><name><surname>D'Elia</surname><given-names>L</given-names></name><name><surname>Cappuccio</surname><given-names>FP</given-names></name></person-group><article-title>Do statins reduce blood pressure? A meta-analysis of randomized,
controlled trials</article-title><source>Hypertension</source><year>2007</year><volume>49</volume><issue>4</issue><fpage>792</fpage><lpage>798</lpage><pub-id pub-id-type="pmid">17309949</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sp&#x000f3;sito</surname><given-names>AC</given-names></name><name><surname>Mansur</surname><given-names>AP</given-names></name><name><surname>Coelho</surname><given-names>OR</given-names></name><name><surname>Nicolau</surname><given-names>JC</given-names></name><name><surname>Ramires</surname><given-names>JA</given-names></name></person-group><article-title>Additional reduction in blood pressure after cholesterol-lowering
treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients
using angiotensin-converting enzyme inhibitors (enalapril or
lisinopril)</article-title><source>Am J Cardiol</source><year>1999</year><volume>83</volume><issue>10</issue><fpage>1497</fpage><lpage>1499</lpage><pub-id pub-id-type="pmid">10335771</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mancia</surname><given-names>G</given-names></name><name><surname>Parati</surname><given-names>G</given-names></name><name><surname>Revera</surname><given-names>M</given-names></name><name><surname>Bilo</surname><given-names>G</given-names></name><name><surname>Giuliano</surname><given-names>A</given-names></name><name><surname>Veglia</surname><given-names>F</given-names></name><etal/></person-group><article-title>Statins, antihypertensive treatment, and blood pressure control in
clinic and over 24 hours: evidence from PHYLLIS randomised double blind
trial</article-title><source>BMJ</source><year>2010</year><volume>340</volume><fpage>c1197</fpage><lpage>c1197</lpage><pub-id pub-id-type="pmid">20339154</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koh</surname><given-names>KK</given-names></name><name><surname>Son</surname><given-names>JW</given-names></name><name><surname>Ahn</surname><given-names>JY</given-names></name><name><surname>Kim</surname><given-names>DS</given-names></name><name><surname>Jin</surname><given-names>DK</given-names></name><name><surname>Kim</surname><given-names>HS</given-names></name><etal/></person-group><article-title>Simvastatin combined with ramipril treatment in hypercholesterolemic
patients</article-title><source>Hypertension</source><year>2004</year><volume>44</volume><issue>2</issue><fpage>180</fpage><lpage>185</lpage><pub-id pub-id-type="pmid">15184351</pub-id></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koh</surname><given-names>KK</given-names></name><name><surname>Quon</surname><given-names>MJ</given-names></name><name><surname>Lee</surname><given-names>Y</given-names></name><name><surname>Han</surname><given-names>SH</given-names></name><name><surname>Ahn</surname><given-names>JY</given-names></name><name><surname>Chung</surname><given-names>WJ</given-names></name><etal/></person-group><article-title>Additive beneficial cardiovascular and metabolic effects of
combination therapy with ramipril and candesartan in hypertensive
patients</article-title><source>Eur Heart J</source><year>2007</year><volume>28</volume><issue>12</issue><fpage>1440</fpage><lpage>1447</lpage><pub-id pub-id-type="pmid">17483542</pub-id></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Gong</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name></person-group><article-title>Meta-analysis of the effects of statin therapy on endothelial function
in patients with diabetes mellitus</article-title><source>Atherosclerosis</source><year>2012</year><volume>223</volume><issue>1</issue><fpage>78</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">22326029</pub-id></element-citation></ref><ref id="r22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Venrooij</surname><given-names>FV</given-names></name><name><surname>van de Ree</surname><given-names>MA</given-names></name><name><surname>Bots</surname><given-names>ML</given-names></name><name><surname>Stolk</surname><given-names>RP</given-names></name><name><surname>Huisman</surname><given-names>MV</given-names></name><name><surname>Banga</surname><given-names>JD</given-names></name></person-group><article-title>Aggressive lipid lowering does not improve endothelial function in
type 2 diabetes: the Diabetes Atorvastatin Lipid Intervention (DALI) Study: a
randomized, double-blind, placebo-controlled trial</article-title><source>Diabetes Care</source><year>2002</year><volume>25</volume><issue>7</issue><fpage>1211</fpage><lpage>1216</lpage><pub-id pub-id-type="pmid">12087021</pub-id></element-citation></ref><ref id="r23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beishuizen</surname><given-names>ED</given-names></name><name><surname>Tamsma</surname><given-names>JT</given-names></name><name><surname>Jukema</surname><given-names>JW</given-names></name><name><surname>van de Ree</surname><given-names>MA</given-names></name><name><surname>van der Vijver</surname><given-names>JCM</given-names></name><name><surname>Meinders</surname><given-names>AE</given-names></name><etal/></person-group><article-title>The effect of statin therapy on endothelial function in type 2
diabetes without manifest cardiovascular disease</article-title><source>Diabetes Care</source><year>2005</year><volume>28</volume><issue>7</issue><fpage>1668</fpage><lpage>1674</lpage><pub-id pub-id-type="pmid">15983318</pub-id></element-citation></ref><ref id="r24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>KCB</given-names></name><name><surname>Chow</surname><given-names>WS</given-names></name><name><surname>Tam</surname><given-names>SCF</given-names></name><name><surname>Ai</surname><given-names>VHG</given-names></name><name><surname>Lam</surname><given-names>CHL</given-names></name><name><surname>Lam</surname><given-names>KSL</given-names></name></person-group><article-title>Atorvastatin lowers C-reactive protein and improves
endothelium-dependent vasodilation in type 2 diabetes mellitus</article-title><source>J Clin Endocrinol Metab</source><year>2002</year><volume>87</volume><issue>2</issue><fpage>563</fpage><lpage>568</lpage><pub-id pub-id-type="pmid">11836286</pub-id></element-citation></ref><ref id="r25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanaki</surname><given-names>AI</given-names></name><name><surname>Sarafidis</surname><given-names>PA</given-names></name><name><surname>Georgianos</surname><given-names>PI</given-names></name><name><surname>Kanavos</surname><given-names>K</given-names></name><name><surname>Tziolas</surname><given-names>IM</given-names></name><name><surname>Zebekakis</surname><given-names>PE</given-names></name><etal/></person-group><article-title>Effects of low-dose atorvastatin on arterial stiffness and central
aortic pressure augmentation in patients with hypertension and
hypercholesterolemia</article-title><source>Am J Hypertens</source><year>2013</year><volume>26</volume><issue>5</issue><fpage>608</fpage><lpage>616</lpage><pub-id pub-id-type="pmid">23449607</pub-id></element-citation></ref><ref id="r26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>B</given-names></name><name><surname>Lacy</surname><given-names>PS</given-names></name><name><surname>Cruickshank</surname><given-names>JK</given-names></name><name><surname>Collier</surname><given-names>D</given-names></name><name><surname>Hughes</surname><given-names>AD</given-names></name><name><surname>Stanton</surname><given-names>A</given-names></name><etal/></person-group><article-title>Impact of statin therapy on central aortic pressures and hemodynamics:
principal results of the Conduit Artery Function Evaluation-Lipid-Lowering Arm
(CAFE-LLA) Study</article-title><source>Circulation</source><year>2009</year><volume>119</volume><issue>1</issue><fpage>53</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">19103995</pub-id></element-citation></ref><ref id="r27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fassett</surname><given-names>RG</given-names></name><name><surname>Robertson</surname><given-names>IK</given-names></name><name><surname>Ball</surname><given-names>MJ</given-names></name><name><surname>Geraghty</surname><given-names>DP</given-names></name><name><surname>Sharman</surname><given-names>JE</given-names></name><name><surname>Coombes</surname><given-names>JS</given-names></name></person-group><article-title>Effects of atorvastatin on arterial stiffness in chronic kidney
disease: a randomised controlled trial</article-title><source>J Atheroscler Thromb</source><year>2010</year><volume>17</volume><issue>3</issue><fpage>235</fpage><lpage>241</lpage><pub-id pub-id-type="pmid">20032570</pub-id></element-citation></ref><ref id="r28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raison</surname><given-names>J</given-names></name><name><surname>Rudnichi</surname><given-names>A</given-names></name><name><surname>Safar</surname><given-names>ME</given-names></name></person-group><article-title>Effects of atorvastatin on aortic pulse wave velocity in patients with
hypertension and hypercholesterolaemia: a preliminary study</article-title><source>J Hum Hypertens</source><year>2002</year><volume>16</volume><issue>10</issue><fpage>705</fpage><lpage>710</lpage><pub-id pub-id-type="pmid">12420194</pub-id></element-citation></ref><ref id="r29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pirro</surname><given-names>M</given-names></name><name><surname>Schillaci</surname><given-names>G</given-names></name><name><surname>Mannarino</surname><given-names>MR</given-names></name><name><surname>Savarese</surname><given-names>G</given-names></name><name><surname>Vaudo</surname><given-names>G</given-names></name><name><surname>Siepi</surname><given-names>D</given-names></name><etal/></person-group><article-title>Effects of rosuvastatin on 3-nitrotyrosine and aortic stiffness in
hypercholesterolemia</article-title><source>Nutr Metab Cardiovasc Dis</source><year>2007</year><volume>17</volume><issue>6</issue><fpage>436</fpage><lpage>441</lpage><pub-id pub-id-type="pmid">17134956</pub-id></element-citation></ref><ref id="r30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>M&#x000e4;ki-Pet&#x000e4;j&#x000e4;</surname><given-names>KM</given-names></name><name><surname>Booth</surname><given-names>AD</given-names></name><name><surname>Hall</surname><given-names>FC</given-names></name><name><surname>Wallace</surname><given-names>SML</given-names></name><name><surname>Brown</surname><given-names>J</given-names></name><name><surname>McEniery</surname><given-names>CM</given-names></name><etal/></person-group><article-title>Ezetimibe and simvastatin reduce inflammation, disease activity, and
aortic stiffness and improve endothelial function in rheumatoid
arthritis</article-title><source>J Am Coll Cardiol</source><year>2007</year><volume>50</volume><issue>9</issue><fpage>852</fpage><lpage>858</lpage><pub-id pub-id-type="pmid">17719471</pub-id></element-citation></ref></ref-list></back></article>